WO1999009998A1 - Use of uridine 5'-diphosphate and analogs thereof for the treatment of lung diseases - Google Patents
Use of uridine 5'-diphosphate and analogs thereof for the treatment of lung diseases Download PDFInfo
- Publication number
- WO1999009998A1 WO1999009998A1 PCT/US1998/017894 US9817894W WO9909998A1 WO 1999009998 A1 WO1999009998 A1 WO 1999009998A1 US 9817894 W US9817894 W US 9817894W WO 9909998 A1 WO9909998 A1 WO 9909998A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- particles
- alkyl
- diphosphate
- compound
- Prior art date
Links
- 0 C*(C1*2)C1C(*NC)=C*(*)C2O Chemical compound C*(C1*2)C1C(*NC)=C*(*)C2O 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/12—Mucolytics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Abstract
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU91249/98A AU9124998A (en) | 1997-08-29 | 1998-08-28 | Use of uridine 5'-diphosphate and analogs thereof for the treatment of lung iseases |
JP2000507388A JP2001513568A (en) | 1997-08-29 | 1998-08-28 | Use of uridine 5'-diphosphate and its analogs for treating lung disease |
KR1020007001997A KR20010023359A (en) | 1997-08-29 | 1998-08-28 | Use of uridine 5'-diphosphate and analogs thereof for the treatment of lung diseases |
AT98943457T ATE288273T1 (en) | 1997-08-29 | 1998-08-28 | USE OF URIDINE 5'-DIPHOSPHATE AND ANALOGUES FOR THE TREATMENT OF LUNG DISEASES |
DE69828892T DE69828892D1 (en) | 1997-08-29 | 1998-08-28 | USE OF URIDINE 5'-DIPHOSPHATE AND ANALOGS FOR THE TREATMENT OF LUNG DISEASES |
CA002300146A CA2300146A1 (en) | 1997-08-29 | 1998-08-28 | Use of uridine 5'-diphosphate and analogs thereof for the treatment of lung diseases |
EP98943457A EP1011688B1 (en) | 1997-08-29 | 1998-08-28 | Use of uridine 5'-diphosphate and analogs thereof for the treatment of lung diseases |
BR9811612-6A BR9811612A (en) | 1997-08-29 | 1998-08-28 | Use of uridine 5'-diphosphate and the like for the treatment of lung diseases |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US5706497P | 1997-08-29 | 1997-08-29 | |
US60/057,064 | 1997-08-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1999009998A1 true WO1999009998A1 (en) | 1999-03-04 |
Family
ID=22008285
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1998/017894 WO1999009998A1 (en) | 1997-08-29 | 1998-08-28 | Use of uridine 5'-diphosphate and analogs thereof for the treatment of lung diseases |
Country Status (14)
Country | Link |
---|---|
US (3) | US6143279A (en) |
EP (1) | EP1011688B1 (en) |
JP (1) | JP2001513568A (en) |
KR (1) | KR20010023359A (en) |
CN (1) | CN1268056A (en) |
AR (1) | AR013454A1 (en) |
AT (1) | ATE288273T1 (en) |
AU (1) | AU9124998A (en) |
BR (1) | BR9811612A (en) |
CA (1) | CA2300146A1 (en) |
DE (1) | DE69828892D1 (en) |
ID (1) | ID29198A (en) |
WO (1) | WO1999009998A1 (en) |
ZA (1) | ZA987847B (en) |
Cited By (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000050024A2 (en) * | 1999-02-26 | 2000-08-31 | Inspire Pharmaceuticals, Inc. | Method of promoting mucosal hydration with certain uridine, adenine and cytidine diphosphates and analogs thereof |
WO2001085764A2 (en) * | 2000-05-11 | 2001-11-15 | Bayer Aktiengesellschaft | Regulation of human p2y-like g protein-coupled receptor |
US6319908B1 (en) | 1996-07-03 | 2001-11-20 | Inspire Pharmaceuticals, Inc. | Method for large-scale production of di(uridine 5′-tetraphosphate) and salts thereof |
WO2003024980A1 (en) * | 2001-09-14 | 2003-03-27 | Universite De Liege | Preparation of triphosphosrylated organic compounds optionally marked with phosphorus 32 or phosphorus 33 |
US6703376B2 (en) | 1996-07-23 | 2004-03-09 | Inspire Pharmaceuticals, Inc. | Use of uridine triphosphates and related compounds for the prevention and treatment of pneumonia in immobilized patients |
US6713458B1 (en) | 1997-07-25 | 2004-03-30 | Inspire Pharmaceuticals, Inc. | Therapeutic uses of di(uridine 5′)-tetraphosphate and salts thereof |
EP1450820A2 (en) * | 2001-11-06 | 2004-09-01 | Inspire Pharmaceuticals, Inc. | Method for treating or preventing inflammatory diseases |
US6864243B1 (en) | 2000-05-12 | 2005-03-08 | Inspire Pharmaceuticals, Inc. | Method for treating retinal degeneration with purinergic receptor agonists |
US6872710B2 (en) | 1997-07-25 | 2005-03-29 | Inspire Pharmaceuticals, Inc. | Di(uridine 5′)-tetraphosphate and salts thereof |
WO2006016115A2 (en) * | 2004-08-11 | 2006-02-16 | University College Cardiff Consultants Limited | Method and means for enhanced pulmonary drug delivery |
US7018985B1 (en) | 2000-08-21 | 2006-03-28 | Inspire Pharmaceuticals, Inc. | Composition and method for inhibiting platelet aggregation |
US7109181B2 (en) | 2001-06-25 | 2006-09-19 | Inspire Pharmaceuticals, Inc. | Joint lubrication with P2Y purinergic receptor agonists |
WO2007083173A2 (en) * | 2006-01-19 | 2007-07-26 | University Of Debrecen | Mononucleotides and mononucleosides for use in therapy |
US7326683B2 (en) | 2004-05-06 | 2008-02-05 | Molichem Medicines, Inc. | Treatment of membrane-associated diseases and disorders using lantibiotic containing compositions |
US7432252B1 (en) | 1997-07-25 | 2008-10-07 | Inspire Pharmaceuticals, Inc. | Method of promoting cervical and vaginal secretions |
US7618949B2 (en) | 2000-08-21 | 2009-11-17 | Inspire Pharmaceuticals, Inc. | Drug-eluting stents coated with P2Y12 receptor antagonist compound |
EP2556832A1 (en) * | 2011-08-12 | 2013-02-13 | Universitätsklinikum Freiburg | Uridine and uridine analogues for use in the treatment of specific lung diseases, namely COPD and pulmonary fibrosis |
US8618074B2 (en) | 2007-03-15 | 2013-12-31 | Board Of Regents Of The University Of Texas System | GPCR enhanced neuroprotection to treat brain injury |
WO2015021358A2 (en) | 2013-08-09 | 2015-02-12 | Dominique Charmot | Compounds and methods for inhibiting phosphate transport |
EP2968385A4 (en) * | 2013-03-13 | 2016-08-10 | Univ Tufts | Uridine nucleoside derivatives, compositions and methods of use |
WO2017075535A1 (en) | 2015-10-28 | 2017-05-04 | Oxeia Biopharmaceuticals, Inc. | Methods of treating neurodegenerative conditions |
US9750760B2 (en) | 2012-09-28 | 2017-09-05 | Tufts University | Uridine diphosphate derivatives, prodrugs, compositions and methods for treating neurodegenerative disorders |
US10105416B2 (en) | 2014-02-05 | 2018-10-23 | The Regents Of The University Of California | Methods of treating mild brain injury |
US10138265B2 (en) | 2013-03-13 | 2018-11-27 | Tufts University | Uridine nucleoside derivatives, compositions and methods of use |
US11072627B2 (en) | 2011-09-30 | 2021-07-27 | Tufts University | Uridine diphosphate derivatives, compositions and methods for treating neurodegenerative disorders |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20010023359A (en) * | 1997-08-29 | 2001-03-26 | 인스파이어 파마슈티컬즈 | Use of uridine 5'-diphosphate and analogs thereof for the treatment of lung diseases |
WO2000039145A1 (en) * | 1998-12-23 | 2000-07-06 | The University Of North Carolina At Chapel Hill | Targeted gene transfer using g protein coupled receptors |
WO2000075365A2 (en) * | 1999-06-08 | 2000-12-14 | University Of Iowa Research Foundation | Compounds and methods to enhance raav transduction |
US7241447B1 (en) * | 1999-10-07 | 2007-07-10 | University Of Iowa Research Foundation | Adeno-associated virus vectors and uses thereof |
WO2003028712A2 (en) * | 2001-09-28 | 2003-04-10 | Universite Libre De Bruxelles | Purinergic and pyrimidinergic receptor agonists for the treatment of activated cd4+ t lymphocyte-mediated immune diseases |
US6858615B2 (en) | 2002-02-19 | 2005-02-22 | Parion Sciences, Inc. | Phenyl guanidine sodium channel blockers |
AU2003217863B9 (en) * | 2002-02-28 | 2009-10-29 | Biota Scientific Management Pty Ltd | Nucleotide mimics and their prodrugs |
US20060035811A1 (en) * | 2002-10-18 | 2006-02-16 | Luis Molina | Methods of treating dry eye disease with lantibiotics |
EP1608763A2 (en) * | 2003-03-31 | 2005-12-28 | University Of Iowa Research Foundation | Compounds and methods to enhance raav transduction |
US20090253714A1 (en) * | 2003-08-20 | 2009-10-08 | Johnson Michael R | Methods of reducing risk of infection from pathogens |
US7745442B2 (en) | 2003-08-20 | 2010-06-29 | Parion Sciences, Inc. | Methods of reducing risk of infection from pathogens |
US7479481B2 (en) * | 2004-05-06 | 2009-01-20 | Molichem Medicines, Inc. | Treatment of ocular diseases and disorders using lantibiotic compositions |
US7368439B2 (en) * | 2005-06-15 | 2008-05-06 | Bar - Ilan University | Dinucleoside poly(borano)phosphate derivatives and uses thereof |
US7851456B2 (en) * | 2005-06-29 | 2010-12-14 | Inspire Pharmaceuticals, Inc. | P2Y6 receptor agonists for treating lung diseases |
US20070021439A1 (en) * | 2005-07-25 | 2007-01-25 | Parion Sciences, Inc. | Methods of reducing risk of infection from pathogens with soluble amide and ester pyrazinoylguanidine sodium channel blockers |
AR086745A1 (en) | 2011-06-27 | 2014-01-22 | Parion Sciences Inc | 3,5-DIAMINO-6-CHLORINE-N- (N- (4- (4- (2- (HEXIL (2,3,4,5,6-PENTAHYDROXIHEXIL)) AMINO) ETOXI) PHENYL) BUTIL) CARBAMIMIDOIL) PIRAZINA -2-CARBOXAMIDE |
US9833207B2 (en) | 2012-08-08 | 2017-12-05 | William Harrison Zurn | Analysis and clearing module, system and method |
PE20151054A1 (en) | 2012-12-17 | 2015-08-07 | Parion Sciences Inc | CHLORINE-PIRAZINE CARBOXAMIDE DERIVATIVES WITH BLOCKING ACTIVITY ON THE EPITHELIAL SODIUM CHANNELS |
RU2018138195A (en) | 2012-12-17 | 2018-12-18 | Пэрион Сайенсиз, Инк. | COMPOUNDS 3,5-DIAMINO-6-CHLORO-N- (N- (4-Phenylbutyl) Carbamimidoyl) Pyrazine-2-Carboxamide |
US9962533B2 (en) | 2013-02-14 | 2018-05-08 | William Harrison Zurn | Module for treatment of medical conditions; system for making module and methods of making module |
US9102633B2 (en) | 2013-12-13 | 2015-08-11 | Parion Sciences, Inc. | Arylalkyl- and aryloxyalkyl-substituted epithelial sodium channel blocking compounds |
WO2017139381A1 (en) | 2016-02-08 | 2017-08-17 | University Of Iowa Research Foundation | Methods to produce chimeric adeno-associated virus/bocavirus parvovirus |
MX2018010842A (en) | 2016-03-07 | 2019-07-04 | Univ Iowa Res Found | Aav-mediated expression using a synthetic promoter and enhancer. |
KR20210077946A (en) * | 2019-12-18 | 2021-06-28 | 주식회사 종근당 | Method of preparing uridine 5’-diphosphate(UDP), salt thereof or hydrate thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2530862A1 (en) * | 1974-07-11 | 1976-01-29 | Chugai Pharmaceutical Co Ltd | MEDICINAL PRODUCTS FOR THE PREVENTION AND TREATMENT OF ALCOHOLISM |
WO1992011016A1 (en) * | 1990-12-22 | 1992-07-09 | Fisons Plc | Pharmaceutical composition containing uridine 5'-triphosphate for the treatment of cystic fibrosis |
WO1994008593A1 (en) * | 1991-06-19 | 1994-04-28 | The University Of North Carolina At Chapel Hill | Method of treating lung disease with uridine triphosphates |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE639386A (en) * | 1962-10-30 | |||
DE2122529A1 (en) * | 1971-05-06 | 1972-12-14 | Max Planck Gesellschaft zur Förde rung der Wissenschaften e V , 3400 Gottin gen | Thiophosphate analogs of the nucleoside di and tnphosphate and processes for their preparation |
JPS5415073B2 (en) * | 1972-09-14 | 1979-06-12 | ||
US4501729A (en) * | 1982-12-13 | 1985-02-26 | Research Corporation | Aerosolized amiloride treatment of retained pulmonary secretions |
DE3709851A1 (en) * | 1987-03-24 | 1988-10-06 | Silica Gel Gmbh Adsorptions Te | NMR DIAGNOSTIC LIQUID COMPOSITIONS |
EP0517573A1 (en) * | 1991-06-05 | 1992-12-09 | Synthelabo | Pharmaceutical compositions for the treatment of airway disorders |
US5656256A (en) * | 1994-12-14 | 1997-08-12 | The University Of North Carolina At Chapel Hill | Methods of treating lung disease by an aerosol containing benzamil or phenamil |
US5635160A (en) * | 1995-06-07 | 1997-06-03 | The University Of North Carolina At Chapel Hill | Dinucleotides useful for the treatment of cystic fibrosis and for hydrating mucus secretions |
US5628984A (en) * | 1995-07-31 | 1997-05-13 | University Of North Carolina At Chapel Hill | Method of detecting lung disease |
US6348589B1 (en) * | 1997-02-06 | 2002-02-19 | Inspire Pharmaceuticals, Inc. | Certain dinucleotides and their use as modulators of mucociliary clearance and ciliary beat frequency |
SE9701219D0 (en) * | 1997-04-04 | 1997-04-04 | Astra Pharma Prod | New compounds |
KR20010023359A (en) * | 1997-08-29 | 2001-03-26 | 인스파이어 파마슈티컬즈 | Use of uridine 5'-diphosphate and analogs thereof for the treatment of lung diseases |
-
1998
- 1998-08-28 KR KR1020007001997A patent/KR20010023359A/en not_active Application Discontinuation
- 1998-08-28 US US09/143,297 patent/US6143279A/en not_active Expired - Lifetime
- 1998-08-28 AR ARP980104305A patent/AR013454A1/en not_active Application Discontinuation
- 1998-08-28 DE DE69828892T patent/DE69828892D1/en not_active Expired - Lifetime
- 1998-08-28 EP EP98943457A patent/EP1011688B1/en not_active Expired - Lifetime
- 1998-08-28 ID IDW991714A patent/ID29198A/en unknown
- 1998-08-28 AU AU91249/98A patent/AU9124998A/en not_active Abandoned
- 1998-08-28 CA CA002300146A patent/CA2300146A1/en not_active Abandoned
- 1998-08-28 WO PCT/US1998/017894 patent/WO1999009998A1/en active IP Right Grant
- 1998-08-28 BR BR9811612-6A patent/BR9811612A/en not_active IP Right Cessation
- 1998-08-28 CN CN98808470A patent/CN1268056A/en active Pending
- 1998-08-28 JP JP2000507388A patent/JP2001513568A/en active Pending
- 1998-08-28 AT AT98943457T patent/ATE288273T1/en not_active IP Right Cessation
- 1998-08-28 ZA ZA987847A patent/ZA987847B/en unknown
-
1999
- 1999-07-13 US US09/352,390 patent/US6022527A/en not_active Expired - Lifetime
-
2000
- 2000-08-24 US US09/645,161 patent/US6451288B1/en not_active Expired - Lifetime
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2530862A1 (en) * | 1974-07-11 | 1976-01-29 | Chugai Pharmaceutical Co Ltd | MEDICINAL PRODUCTS FOR THE PREVENTION AND TREATMENT OF ALCOHOLISM |
WO1992011016A1 (en) * | 1990-12-22 | 1992-07-09 | Fisons Plc | Pharmaceutical composition containing uridine 5'-triphosphate for the treatment of cystic fibrosis |
WO1994008593A1 (en) * | 1991-06-19 | 1994-04-28 | The University Of North Carolina At Chapel Hill | Method of treating lung disease with uridine triphosphates |
Non-Patent Citations (1)
Title |
---|
K.N. OLIVER ET AL.: "Acute safety and effects on mucociliary clearance of aerosolized uridine 5'-triphosphate +/- amiloride in normal human adults", AM. J. RESPIR. CRIT. CARE MED., vol. 154, 1996, pages 217 - 223, XP002056054 * |
Cited By (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6319908B1 (en) | 1996-07-03 | 2001-11-20 | Inspire Pharmaceuticals, Inc. | Method for large-scale production of di(uridine 5′-tetraphosphate) and salts thereof |
US6703376B2 (en) | 1996-07-23 | 2004-03-09 | Inspire Pharmaceuticals, Inc. | Use of uridine triphosphates and related compounds for the prevention and treatment of pneumonia in immobilized patients |
US7432252B1 (en) | 1997-07-25 | 2008-10-07 | Inspire Pharmaceuticals, Inc. | Method of promoting cervical and vaginal secretions |
US7939510B2 (en) | 1997-07-25 | 2011-05-10 | Inspire Pharmaceuticals, Inc. | Di(uridine 5′-)tetraphosphate and salts thereof |
US6713458B1 (en) | 1997-07-25 | 2004-03-30 | Inspire Pharmaceuticals, Inc. | Therapeutic uses of di(uridine 5′)-tetraphosphate and salts thereof |
US6765090B2 (en) | 1997-07-25 | 2004-07-20 | Inspire Pharmaceuticals, Inc. | Method for large-scale production of di(uridine 5')-tetraphosphate and salts thereof |
US7132410B2 (en) | 1997-07-25 | 2006-11-07 | Inspire Pharmaceuticals, Inc. | Di(uridine 5′-)tetraphosphate and salts thereof |
US7091334B2 (en) | 1997-07-25 | 2006-08-15 | Inspire Pharmaceuticals, Inc. | Method for large-scale production of di(uridine 5′)-tetraphosphate and salts thereof |
US6872710B2 (en) | 1997-07-25 | 2005-03-29 | Inspire Pharmaceuticals, Inc. | Di(uridine 5′)-tetraphosphate and salts thereof |
WO2000050024A3 (en) * | 1999-02-26 | 2001-07-05 | Inspire Pharmaceuticals Inc | Method of promoting mucosal hydration with certain uridine, adenine and cytidine diphosphates and analogs thereof |
WO2000050024A2 (en) * | 1999-02-26 | 2000-08-31 | Inspire Pharmaceuticals, Inc. | Method of promoting mucosal hydration with certain uridine, adenine and cytidine diphosphates and analogs thereof |
WO2001085764A2 (en) * | 2000-05-11 | 2001-11-15 | Bayer Aktiengesellschaft | Regulation of human p2y-like g protein-coupled receptor |
WO2001085764A3 (en) * | 2000-05-11 | 2002-11-28 | Bayer Ag | Regulation of human p2y-like g protein-coupled receptor |
US6864243B1 (en) | 2000-05-12 | 2005-03-08 | Inspire Pharmaceuticals, Inc. | Method for treating retinal degeneration with purinergic receptor agonists |
US7018985B1 (en) | 2000-08-21 | 2006-03-28 | Inspire Pharmaceuticals, Inc. | Composition and method for inhibiting platelet aggregation |
US7618949B2 (en) | 2000-08-21 | 2009-11-17 | Inspire Pharmaceuticals, Inc. | Drug-eluting stents coated with P2Y12 receptor antagonist compound |
US7109181B2 (en) | 2001-06-25 | 2006-09-19 | Inspire Pharmaceuticals, Inc. | Joint lubrication with P2Y purinergic receptor agonists |
WO2003024980A1 (en) * | 2001-09-14 | 2003-03-27 | Universite De Liege | Preparation of triphosphosrylated organic compounds optionally marked with phosphorus 32 or phosphorus 33 |
EP1450820A4 (en) * | 2001-11-06 | 2009-02-18 | Inspire Pharmaceuticals Inc | Method for treating or preventing inflammatory diseases |
EP1450820A2 (en) * | 2001-11-06 | 2004-09-01 | Inspire Pharmaceuticals, Inc. | Method for treating or preventing inflammatory diseases |
US7256183B2 (en) | 2001-11-06 | 2007-08-14 | Inspire Pharmaceuticals, Inc. | Method for treating or preventing inflammatory diseases |
US7326683B2 (en) | 2004-05-06 | 2008-02-05 | Molichem Medicines, Inc. | Treatment of membrane-associated diseases and disorders using lantibiotic containing compositions |
WO2006016115A2 (en) * | 2004-08-11 | 2006-02-16 | University College Cardiff Consultants Limited | Method and means for enhanced pulmonary drug delivery |
WO2006016115A3 (en) * | 2004-08-11 | 2006-06-08 | Univ Cardiff | Method and means for enhanced pulmonary drug delivery |
WO2007083173A3 (en) * | 2006-01-19 | 2013-10-17 | University Of Debrecen | Mononucleotides and mononucleosides for use in therapy |
WO2007083173A2 (en) * | 2006-01-19 | 2007-07-26 | University Of Debrecen | Mononucleotides and mononucleosides for use in therapy |
US8618074B2 (en) | 2007-03-15 | 2013-12-31 | Board Of Regents Of The University Of Texas System | GPCR enhanced neuroprotection to treat brain injury |
US9795625B2 (en) | 2011-08-12 | 2017-10-24 | Universitaetsklinikum Freiburg | Uridine and uridine analogues for treatment of specific lung diseases, namely COPD and pulmonary fibrosis |
EP2556832A1 (en) * | 2011-08-12 | 2013-02-13 | Universitätsklinikum Freiburg | Uridine and uridine analogues for use in the treatment of specific lung diseases, namely COPD and pulmonary fibrosis |
WO2013023882A1 (en) | 2011-08-12 | 2013-02-21 | Universitätsklinikum Freiburg | Uridine and uridine analogues for treatment of specific lung diseases, namely copd and pulmonary fibrosis |
US9333216B2 (en) | 2011-08-12 | 2016-05-10 | Universitaetsklinikum Freiburg | Uridine and uridine analogues for treatment of specific lung diseases, namely COPD and pulmonary fibrosis |
US11072627B2 (en) | 2011-09-30 | 2021-07-27 | Tufts University | Uridine diphosphate derivatives, compositions and methods for treating neurodegenerative disorders |
US11241450B2 (en) | 2012-09-28 | 2022-02-08 | Tufts University | Uridine diphosphate derivatives, prodrugs, compositions and uses thereof |
US9750760B2 (en) | 2012-09-28 | 2017-09-05 | Tufts University | Uridine diphosphate derivatives, prodrugs, compositions and methods for treating neurodegenerative disorders |
US10632138B2 (en) | 2012-09-28 | 2020-04-28 | Tufts University | Uridine diphosphate derivatives, prodrugs, compositions and uses thereof |
US9913855B2 (en) | 2012-09-28 | 2018-03-13 | Tufts University | Uridine diphosphate derivatives, prodrugs, compositions and uses thereof |
US10544183B2 (en) | 2013-03-13 | 2020-01-28 | Tufts University | Uridine nucleoside derivatives, compositions and methods of use |
US10138265B2 (en) | 2013-03-13 | 2018-11-27 | Tufts University | Uridine nucleoside derivatives, compositions and methods of use |
EP3449925A1 (en) * | 2013-03-13 | 2019-03-06 | Tufts University | Uridine nucleoside derivatives, compositions and methods of use |
AU2014243707B2 (en) * | 2013-03-13 | 2018-08-30 | Tufts University | Uridine nucleoside derivatives, compositions and methods of use |
EP2968385A4 (en) * | 2013-03-13 | 2016-08-10 | Univ Tufts | Uridine nucleoside derivatives, compositions and methods of use |
US11124536B2 (en) | 2013-03-13 | 2021-09-21 | Tufts University | Uridine nucleoside derivatives, compositions and methods of use |
EP3492106A1 (en) | 2013-08-09 | 2019-06-05 | Ardelyx, Inc. | Compounds and methods for inhibiting phosphate transport |
EP3884935A1 (en) | 2013-08-09 | 2021-09-29 | Ardelyx, Inc. | Compounds and methods for inhibiting phosphate transport |
WO2015021358A2 (en) | 2013-08-09 | 2015-02-12 | Dominique Charmot | Compounds and methods for inhibiting phosphate transport |
US10105416B2 (en) | 2014-02-05 | 2018-10-23 | The Regents Of The University Of California | Methods of treating mild brain injury |
US10617740B2 (en) | 2014-02-05 | 2020-04-14 | The Regents Of The University Of California | Methods of treating mild brain injury |
US11241483B2 (en) | 2014-02-05 | 2022-02-08 | The Regents Of The University Of California | Methods of treating mild brain injury |
WO2017075535A1 (en) | 2015-10-28 | 2017-05-04 | Oxeia Biopharmaceuticals, Inc. | Methods of treating neurodegenerative conditions |
Also Published As
Publication number | Publication date |
---|---|
US6143279A (en) | 2000-11-07 |
BR9811612A (en) | 2000-08-08 |
AR013454A1 (en) | 2000-12-27 |
DE69828892D1 (en) | 2005-03-10 |
ZA987847B (en) | 1999-06-28 |
EP1011688B1 (en) | 2005-02-02 |
CA2300146A1 (en) | 1999-03-04 |
CN1268056A (en) | 2000-09-27 |
JP2001513568A (en) | 2001-09-04 |
US6451288B1 (en) | 2002-09-17 |
ATE288273T1 (en) | 2005-02-15 |
KR20010023359A (en) | 2001-03-26 |
ID29198A (en) | 2001-08-09 |
US6022527A (en) | 2000-02-08 |
EP1011688A1 (en) | 2000-06-28 |
AU9124998A (en) | 1999-03-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1011688B1 (en) | Use of uridine 5'-diphosphate and analogs thereof for the treatment of lung diseases | |
US5876700A (en) | Methods of hydrating lung mucous secretions with benzamil or phenamil | |
EP0938322B1 (en) | Use of uridine triphosphate related compounds for the prevention and treatment of pneumonia in immobilized patients | |
US8158776B2 (en) | P2Y6 receptor agonists for treating lung diseases | |
EP0831777B1 (en) | Dinucleotides useful for the treatment of lung disease | |
US6926911B1 (en) | Compounds and methods for the treatment of airway diseases and for the delivery of airway drugs | |
JP5357857B2 (en) | Anticancer agent and DNA replication inhibitor | |
US20100150898A1 (en) | Compounds and methods for the treatment of airway diseases and for the delivery of airway drugs | |
EP0941099B1 (en) | Treatment of bronchitis with diuridine tetraphosphate | |
TW200817343A (en) | Method of enhancing mucosal hydration and mucosal clearance by treatment with sodium channel blockers and osmolytes | |
WO1994008593A1 (en) | Method of treating lung disease with uridine triphosphates | |
US6673779B2 (en) | Method of treating ciliary dyskinesia with dinucleoside polyphosphate compounds or UTP analogues | |
MXPA00002092A (en) | Use of uridine 5'-diphosphate and analogs thereof for the treatment of lung diseases | |
US5859058A (en) | Nitric oxide synthase inhibitors for inhibiting the production of airway mucas | |
US20210380518A1 (en) | Compounds and methods of using compounds for treatment of respiratory diseases | |
Boucher et al. | Mechanisms and therapeutic actions of uridine triphosphate in the lung |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 98808470.8 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AT AU AZ BA BB BG BR BY CA CH CN CU CZ CZ DE DE DK DK EE EE ES FI FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 91249/98 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 502387 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1998943457 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2300146 Country of ref document: CA Ref document number: 2300146 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020007001997 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2000/002092 Country of ref document: MX |
|
ENP | Entry into the national phase |
Ref document number: 2000 507388 Country of ref document: JP Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 1998943457 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1020007001997 Country of ref document: KR |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1020007001997 Country of ref document: KR |
|
WWG | Wipo information: grant in national office |
Ref document number: 1998943457 Country of ref document: EP |